Literature DB >> 8230444

Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation.

E K Subbarao1, Y Kawaoka, B R Murphy.   

Abstract

Live attenuated influenza A virus vaccines are currently produced by the transfer of attenuating genes from a donor virus to new epidemic variants of influenza A virus, with the selection of reassortant viruses that possess the protective antigens (i.e., the two surface glycoproteins) of the epidemic virus and the attenuating genes from the donor virus. The previously studied attenuated donor viruses were produced by conventional methods such as passage of virus at low temperature or chemical mutagenesis. The present paper describes a new strategy for the generation of a donor virus bearing an attenuating, non-surface-glycoprotein gene. This strategy involves the introduction of attenuating mutations into the cDNA copy of the PB2 polymerase gene by site-directed mutagenesis, transfection of in vitro RNA transcripts of PB2 cDNA, and recovery of the transfected PB2 gene into an infectious virus. An avian-human influenza A virus PB2 single-gene reassortant virus (with an avian influenza A virus PB2 gene) that replicates efficiently in avian tissue but poorly in mammalian cells was used as a helper virus to rescue a transfected synthetic RNA derived from a human influenza A virus PB2 gene. The desired human influenza A virus mutant PB2 transfectant was favored in this situation because the avian influenza A virus PB2 gene restricts viral replication in mammalian cells in culture, the system used for rescue, thereby providing strong selection for the virus bearing the human influenza A virus PB2 gene. We validated the feasibility of this approach by rescuing the PB2 gene of the wild-type influenza A/Ann Arbor/6/60 virus and a mutant derivative that had a single amino acid substitution introduced at position 265 by site-directed mutagenesis. Previously, this amino acid substitution had been shown to specify both a temperature-sensitive (ts) and an attenuation (att) phenotype. The rescued mutant 265 PB2 transfectant virus exhibited the ts and att phenotypes, which confirms that these phenotypes were specified by this single amino acid substitution. The transfectant virus was immunogenic and protected hamsters from subsequent challenge with wild-type virus. The cDNA copy of this influenza A/Ann Arbor/6/60 virus mutant 265 PB2 gene will be used as a substrate for the introduction of additional attenuating mutations by site-directed mutagenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230444      PMCID: PMC238184     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

1.  Amplification, expression, and packaging of foreign gene by influenza virus.

Authors:  W Luytjes; M Krystal; M Enami; J D Parvin; P Palese
Journal:  Cell       Date:  1989-12-22       Impact factor: 41.582

2.  The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys.

Authors:  M H Snyder; A J Buckler-White; W T London; E L Tierney; B R Murphy
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

3.  Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.

Authors:  M H Snyder; R F Betts; D DeBorde; E L Tierney; M L Clements; D Herrington; S D Sears; R Dolin; H F Maassab; B R Murphy
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

4.  An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice.

Authors:  T Muster; E K Subbarao; M Enami; B R Murphy; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

5.  Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2).

Authors:  N J Cox; F Kitame; A P Kendal; H F Maassab; C Naeve
Journal:  Virology       Date:  1988-12       Impact factor: 3.616

6.  Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo.

Authors:  M D Tolpin; J G Massicot; M G Mullinix; H W Kim; R H Parrott; R M Chanock; B R Murphy
Journal:  Virology       Date:  1981-07-30       Impact factor: 3.616

7.  High-efficiency formation of influenza virus transfectants.

Authors:  M Enami; P Palese
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

8.  Promoter analysis of influenza virus RNA polymerase.

Authors:  J D Parvin; P Palese; A Honda; A Ishihama; M Krystal
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Introduction of site-specific mutations into the genome of influenza virus.

Authors:  M Enami; W Luytjes; M Krystal; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

10.  Virulence of avian influenza A viruses for squirrel monkeys.

Authors:  B R Murphy; V S Hinshaw; D L Sly; W T London; N T Hosier; F T Wood; R G Webster; R M Chanock
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

View more
  29 in total

1.  The next influenza pandemic: can it be predicted?

Authors:  Jeffery K Taubenberger; David M Morens; Anthony S Fauci
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

2.  Mammalian adaptation in the PB2 gene of avian H5N1 influenza virus.

Authors:  Ji-Young Min; Celia Santos; Adam Fitch; Alan Twaddle; Yoshiko Toyoda; Jay V DePasse; Elodie Ghedin; Kanta Subbarao
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

3.  Flow Cytometric and Cytokine ELISpot Approaches To Characterize the Cell-Mediated Immune Response in Ferrets following Influenza Virus Infection.

Authors:  Anthony DiPiazza; Katherine Richards; Frances Batarse; Laura Lockard; Hui Zeng; Adolfo García-Sastre; Randy A Albrecht; Andrea J Sant
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

4.  Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein.

Authors:  M R Castrucci; Y Kawaoka
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

Review 5.  Negative-strand RNA viruses: genetic engineering and applications.

Authors:  P Palese; H Zheng; O G Engelhardt; S Pleschka; A García-Sastre
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 6.  Transmission of influenza A viruses.

Authors:  Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Virology       Date:  2015-03-24       Impact factor: 3.616

7.  Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses.

Authors:  Bin Zhou; Yan Li; Scott D Speer; Anju Subba; Xudong Lin; David E Wentworth
Journal:  Vaccine       Date:  2012-03-24       Impact factor: 3.641

Review 8.  Emerging respiratory viruses: challenges and vaccine strategies.

Authors:  Laura Gillim-Ross; Kanta Subbarao
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 9.  Stimulus-responsive viral vectors for controlled delivery of therapeutics.

Authors:  Mitchell J Brun; Eric J Gomez; Junghae Suh
Journal:  J Control Release       Date:  2017-08-24       Impact factor: 9.776

10.  A plasmid-based reverse genetics system for influenza A virus.

Authors:  S Pleschka; R Jaskunas; O G Engelhardt; T Zürcher; P Palese; A García-Sastre
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.